ALLR · Allarity Therapeutics, Inc.
AI read · Good for ALLR
The AI's read
That gives Allarity stronger protection for the dosing plan it expects to test in later trials, and may help it seek partners. But stenoparib remains in Phase 2, and the company says it still needs clinical results to support an FDA application. A patent protects an approach. It does not show that the drug helps patients.